These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A very promising, possibly toxic drug.
    Journal: Treat Rev; 1995; (no 19):5. PubMed ID: 11362757.
    Abstract:
    The drug cidofovir, also known as HPMPC, is now in clinical trials. In earlier studies, cidofovir caused kidney damage (renal toxicity), although it also had strong anti-CMV activity. Of interest is that the second infusion of drug is equally effective as the first infusion (given seven days previously). It is not known if the drug ever stops working; currently, ganciclovir and foscarnet cease to be effective at approximately six months, and the disease progresses. Research has shown that cidofovir is most effective when given once weekly. A new trial has opened that is investigating cidofovir administered once a week for the first two weeks, then subsequently administered biweekly. Potential participants must have failed previous treatments. These patients will all receive the first two weeks of cidofovir, and will then be randomized to two different doses. Participants will receive probenecid and saline hydration to help impede liver damage and to limit renal toxicity. Interested parties can contact The Network at 800-734-7104.
    [Abstract] [Full Text] [Related] [New Search]